Dorzolamide-timolol
Phase 3Small molecule
Dorzolamide-timolol is one of 56 small molecule programs targeting Open-Angle Glaucoma. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Open-Angle Glaucoma
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Travatan
NovartisApproved
Namenda
AbbVieApproved
Zolymbus
AbbVieApproved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Adrucil
EElorac, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Open-Angle Glaucoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dorzolamide-timolol. EMBL-EBI & Wellcome Sanger Institute.
- [4]